Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Sunil J. Wimalawansa
-- 1885 2023-09-06 00:54:55 |
2 layout & references
Sirius Huang
 -5 word(s) 1880 2023-09-06 03:45:51 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Wimalawansa, S.J. Vitamin D—Innate and Acquired Immunity. Encyclopedia. Available online: https://encyclopedia.pub/entry/48859 (accessed on 03 May 2024).
Wimalawansa SJ. Vitamin D—Innate and Acquired Immunity. Encyclopedia. Available at: https://encyclopedia.pub/entry/48859. Accessed May 03, 2024.
Wimalawansa, Sunil J.. "Vitamin D—Innate and Acquired Immunity" Encyclopedia, https://encyclopedia.pub/entry/48859 (accessed May 03, 2024).
Wimalawansa, S.J. (2023, September 06). Vitamin D—Innate and Acquired Immunity. In Encyclopedia. https://encyclopedia.pub/entry/48859
Wimalawansa, Sunil J.. "Vitamin D—Innate and Acquired Immunity." Encyclopedia. Web. 06 September, 2023.
Vitamin D—Innate and Acquired Immunity
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu15173842

Globally, vitamin D deficiency is a significant public health problem—a pandemic—that has overtaken iron deficiency as the most common nutritional deficiency in the world. Vitamin D deficiency is associated with many chronic diseases and increases the risk of acute and worsened chronic infections. Both vitamin D and [25(OH]D: calcifediol) and its active form, 1,25-dihydroxyvitamin D [1,25(OH)2D: calcitriol], play critical roles in protecting humans from invasive pathogens, reducing risks of autoimmunity, and maintaining better health. Conversely, low 25(OH)D status increases susceptibility to infections and developing autoimmunity. Individuals obtain optimal results by maintaining serum 25(OH)D concentrations above 50 ng/mL (125 nmol/L) (above 40 ng/mL in the population): this also minimizes community outbreaks and autoimmune disorders. In over 97.5% of people, this can be achieved through daily sun exposure (except in countries far from the equator during winter) or taking between 5,000 and 8,000 IU vitamin D supplements daily (average, ~70 to 90 IU/kg body weight). Only those with gastrointestinal malabsorption, obesity, or on medications that increase catabolism of vitamin D, and a few specific disorders require higher intake.

25(OH)D epidemiology morbidity

1. Introduction

1,25-dihydroxycholecalciferol (calciferol) is the most active vitamin D metabolite and a potent immune modulator essential for combating pathogens [1][2]. As described below, the circulating hormonal form of calcitriol does not affect immune cell functions. The functionality of these cells depends on adequate generation of calcitriol within them. Calcitriol (i) activates cytosol’s vitamin D (calcitriol)receptors (VDRs), then the complex, translocates into the nucleus to modulate genomic functions, and (ii) acts as signaling molecules for its non-genomic actions, membrane effects, and autocrine and paracrine signaling.
Calcitriol concentrations in the circulation are controlled mostly by parathyroid hormone (PTH) partly via circulatory ionized calcium. In contrast, in target tissues, the production of calcitriol is mostly regulated by circulatory 25(OH)D concentration and the feedback catabolic activity of tissue 24-hydroxylase enzyme, not by PTH. Except for providing as a vital substrate, vitamin D has no demonstrable action: it is measured only in research. Consequently, vitamin D physiologic correlations are focused on the serum 25(OH)D concentration.

2. Vitamin D Activates Immune Cells

The calcitriol—receptor complex translocates to the nucleus, where it binds to the upstream DNA, and modulates over 1200 genes [3]. Calcitriol down-regulates inflammation and oxidative stress, primarily by suppressing inflammatory cytokines. The immunomodulatory effects of vitamin D include activation of immune cells such as T and B cells and macrophage and dendritic cells, as well as increased production of antimicrobial peptides and neutralizing antibodies [4][5][6].
As with COVID-19 multiple infections, vaccines, and repeated bivalent COVID-19 booster doses, cause immune paresis, increasing the vulnerability to infections, especially to intracellular bacteria such as tuberculosis and [7] and respiratory viruses [8][9], and SARS-CoV-2 [10][11][12], especially in those with hypovitaminosis D, leading to severe complications. Those who developed complications and died from it had a high prevalence of vitamin D deficiency—serum 25(OH)D concentrations less than 12 ng/mL (p = 0.004), compared with those with negative results [13].
In addition, vulnerable people—older people with comorbidities—low vitamin D strongly correlate with cytokine storm—a hyper-inflammatory condition caused by an uncontrolled, overactive immune status, with high mortality [14]. Symptomatic disease, complications, and deaths from viral infections, including SARS-CoV-2, are due to weak immune systems and high viral load. Vitamin D does not totally prevent viral infections (i.e., contracting COVID-19), it significantly reduces symptomatic disease, complications, and deaths [12][15][16][17][18][19][20].
Unsurprisingly, having pre-pandemic hypovitaminosis D increases these risks and vulnerability [21][22][23][24]. Similarly, vitamin D deficiency at diagnosis of SARS-CoV-2 markedly increases the severity and mortality [12][17][25][26]. Whereas vitamin D sufficiency is protective against severe COVID-19 disease and deaths (p<0.01) [15][17][27][28]. Overall data confirmed Bradford Hill criteria [29]—vitamin D deficiency as a cause for infection, severity, and mortality from SARS-CoV-2 virus [12][15][16][17][18][19][20].
Vitamin D controls autoimmunity by suppressing adaptive immunity via T- and B-lymphocyte activity [30]. Therefore, hypovitaminosis D causes immune dysfunction; a prime reason for autoimmune responses [31][32][33][34][35], worsens existing autoimmune diseases [36][37], such as multiple sclerosis (MS) [38], and increases risks for autoimmune diseases [34][35]. Persons with several autoimmune disorders, such as type 1 diabetes, autoimmune adrenal disease, MS, Hashimoto’s thyroiditis, etc., consistently have lower concentrations of serum 25(OH)D (calcifediol) [32][33][39]. Data also supports a strong inverse relationship between vitamin D status and autoimmunity—the lower the serum 25(OH)D concentrations, the higher the risks for autoimmunity—incidence and severity [33][34][35]. Figure 1 summarizes the critical negative outcomes of chronic vitamin D deficiency.
Nutrients 15 03842 g003
Figure 1. Major negative consequences are categorized into groups of chronic vitamin D deficiency.
In contrast, vitamin D sufficiency reduces not only acute infections like SARS-CoV-2 but also the risks of chronic infections, such as tuberculosis. Sufficient generation of calcitriol within the immune cells regulates innate and adaptive immunity, potentiating the innate response (monocytes/macrophages with anti-microbial activity) [40][41][42][43][44]. Calcitriol also modulates B lymphocytes and plasma cells for immunoglobulin production and stabilizes B-cells [30][45], increasing anti-microbial peptide synthesis.

3. Modes of Stimulating the Immune System by Vitamin D

Following interactions of vitamin D and VDR (genomic interactions) [31], and activating membrane and signaling systems (non-genomic actions) in immune cells leads to control of inflammation and oxidative stress, increased anti-inflammatory responses [46], and decreased autoimmune tendencies [47]. However, those with sustained hypovitaminosis D have less effective innate and adaptive immune systems. Impaired genomic activity results in hypo-responsivity of autoreactive T cells [48][49]. In contrast, when 25(OH)D concentrations are adequate, T-cell responsiveness is restored, and autoimmunity risks are reduced [45].
The active form of vitamin D calcitriol is essential for modulating immune cells, such as monocytes, macrophages, dendritic cells, and T and B lymphocytes [49][50]. These cells express the enzyme CYP27B1 that hydroxylase calcifediol [25(OH)D] to calcitriol and synthesize VDR) [49][50]. These interactions produce anti-microbial peptides, such as cathelicidin and β-defensin 2. In infected cells, calcitriol increases the expression of nucleotide-binding oligomerization domain-containing protein 2, which damages the cell membranes of bacteria and viruses by activating signaling cascades [45].
In addition to anti-microbial peptides, calcitriol induces autophagy and gap protein [51] which strengthens gap junctions [52] and the integrity of epithelial and endothelial cells, preventing viral penetration and fluid leaks [53]. Vitamin D also enhances the expression of angiotensin-converting enzyme-2 (ACE-2) [54], suppressing the renin–angiotensin system and dampening inflammation [55]. Increased expression of soluble ACE-2 neutralizes circulatory viruses, preventing SARS-CoV-2 from binding to cell membrane-bound ACE-2 receptors and cellular entry [56][57].

4. Vitamin D and Immune System

Evaluation of epidemiological studies illustrates that vitamin D deficiency significantly increases the susceptibility to infections and autoimmunity [31][33][35][58], and acquired autoimmunity [32]. 1α-hydroxylase (CYP27B1) and VDR are expressed in all immune cells, including by neutrophils, lymphocytes, dendritic cells, macrophages (antigen-presenting cells), and B lymphocytes, CD4+, and CD8+: these are stimulated when pathogens and foreign antigens are detected by Toll-like receptors-4 (TLR-4) [58][59].
With intracellular signaling initiated by sufficient calcitriol, accelerate 1α-hydroxylation of 25(OH)D to 1,25-(OH)2D and synthesis of VDR. Calcitriol then suppresses the transcription of inflammatory cytokines and blocks IgE-mediated mast cell degranulation. The latter is one of the mechanisms to alleviate hives, allergic reactions, and disorders that exacerbate inflammation [45]. In contrast, vitamin D adequacy stabilizes mast cells, suppressing the release of histamine and TNF-α [31].
Vitamin D modulates several types of immune cells, including monocytes/macrophages, dendritic cells, and B and T cells [44]. Hypovitaminosis D increases vulnerability to inflammatory diseases and disorders with an autoimmune element, such as lupus, metabolic syndrome, and T1D [60][61][62][63][64] (see below). Following supplementing with vitamin D, clinically meaningful disease risk reductions have been reported in persons with MS, chronic fatigue syndrome, Behcet’s disease, inflammatory bowel diseases [50][65][66][67], and rheumatoid arthritis [68][69]. However, not all study results agree [70][71].
In addition to the anti-inflammatory effects of vitamin D on T-helper cells, B cells, macrophages, and dendritic cells, vitamin D has broader immunomodulatory actions on innate and adaptive immune responses [72][73]. Regulation of immune responses by calcitriol partially inhibits B-cell expressing IgE and increases expression of IL-10, via dendritic cells and T cells [48][74][75][76]. The following section discusses some non-genomic effects of calcitriol on the immune cells.

5. Vitamin D Is Fundamental to the Defense against Microbes and Preventing Autoimmunity

Vitamin D deficiency leads to a dysfunctional immune system, creating increased susceptibility to bacterial infections, mainly intracellular bacterial infections [77][78], such as mycobacteria tuberculosis [79][80], and a variety of viral infections, including influenza A [9][78][81] (Table 1). In contrast, adequate circulating 25(OH)D concentrations are associated with decreased incidences of infections [82], enhanced immunity, and improved ability to overcome bacterial and viral infections [78][83]. Table 1 illustrates some examples of infections and autoimmune disorders improved with adequate serum 25(OH)D concentrations, demonstrating multiple mechanisms; calcitriol combats pathogens [84][85] and prevents autoimmunity [1][2] (Table 1).
Table 1. Infections and autoimmune diseases significantly improved by vitamin D *.
Examples of Infections Autoimmune Diseases and Others
Tuberculosis, leprosy, common cold (intracellular microorganisms) Allergy/eczema
Influenza type A $ Asthma
Coryza (common cold) Chronic hives
Upper respiratory tract infections Fibromyalgia
Lower urinary tract infections Inflammatory bowel disease
Bacterial vaginosis in pregnant women Multiple sclerosis
Periodontal gum disease and infections Myositis and periostitis
Osteonecrosis of the jaw Primary biliary cirrhosis
Miscellaneous fungal infections Psoriasis
Yeast infection Polyautoimmunity
Coxsackie A and B Rheumatoid arthritis/ Behcet’s disease
SARS-CoV-2 Type 1 diabetes mellitus
* From multiple sources, including http://www.vitamindwiki.com/VitaminDWiki (accessed on 10 May 2023) [86][87][88]. $ Influenza type B risk is not affected by vitamin D status [89]. 

6. The Importance of Intracellular Generation of Calcitriol for Immune Cell Signaling

Approximately 75% of the innate [1] and over 50% of the adaptive immune systems [90] are driven by intracellularly generated calcitriol [91]. However, present hormonal calcitriol has little or no effect on intracellular signal transduction or genomic functions in immune cells. Therefore, administration of pharmacological doses of calcitriol should be avoided in infections. The correct approach is to provide appropriate higher doses of vitamin D (including an upfront loading dose if indicated) [92], except for oral administration of calcifediol in emergencies [84][91].

Intracellular calcitriol is critical for modulating both genomic [93] and non-genomic activities like signal transduction [94][95]. The latter includes the tightening of gap-junctions [96] and autocrine (intracrine) and paracrine signaling [5][6][84]. Intracrine functions are initiated following the detection of foreign proteins, microbes, etc., by a series of cell surface receptors: the most important is the membrane-bound (sensing/detecting) Toll-like receptor-4 TLR-4 [97], which is also involved in the production of antimicrobial peptides [59]. Intermittent signals derived from TLR-4 - lead to over-drive peak production of calcitriol and VDR in microsomes [98] (see below for details). However, calcitriol is indicated in calcitriol/VDR-resistant syndromes, hypoparathyroidism, and chronic renal failure, where exogenous calcitriol is lifesaving [99].

When circulating D3 and/or 25(OH)D is adequate (e.g., over 50 ng/mL), they diffuse into immune cells, facilitating the generation of calcitriol intracellualrly. Calcitriol suppresses the pathological process and hyper-immune reactions with its genomic actions and autocrine signaling mechanisms [5][6]. These actions reduce the risks of cytokine storms and ARDS and are associated with severe pulmonary and cardiovascular complications in persons with severe infections like COVID-19 [100][101].

7. Conclusion

Maintenance of sufficient circulating 25(OH)D has a profound helpful effect on the musculoskeletal system, decreasing many common disorders. In addition to its endocrine effects, vitamin D exerts genomic and crucial autocrine and paracrine effects in peripheral target tissues subject to epigenesis modulation [102]. Maintaining mean population vitamin D status—serum 25(OH)D concentrations— above 40 ng/mL leads to broader benefits and reduced healthcare costs. This will significantly impact achieving full physiological benefits, including reducing the risks of chronic diseases, infections, and all-cause mortality [103]. This is the most cost-effective approach, instead of treating people after developing complications from chronic hypovitaminosis D and many related disease conditions. Therefore, adopting this to clinical practice guidelines and healthcare insurance protocols is warranted.

References

  1. Zdrenghea, M.T.; Makrinioti, H.; Bagacean, C.; Bush, A.; Johnston, S.L.; Stanciu, L.A. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev. Med. Virol. 2017, 27, e1909.
  2. Gotelli, E.; Soldano, S.; Hysa, E.; Paolino, S.; Campitiello, R.; Pizzorni, C.; Sulli, A.; Smith, V.; Cutolo, M. Vitamin D and COVID-19: Narrative Review after 3 Years of Pandemic. Nutrients 2022, 14, 4907.
  3. Hanel, A.; Bendik, I.; Carlberg, C. Transcriptome-Wide Profile of 25-Hydroxyvitamin D3 in Primary Immune Cells from Human Peripheral Blood. Nutrients 2021, 13, 4100.
  4. Aygun, H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn-Schmiedeberg's Arch. Pharmacol. 2020, 393, 1157–1160.
  5. Chauss, D.; Freiwald, T.; McGregor, R.; Yan, B.; Wang, L.; Nova-Lamperti, E.; Kumar, D.; Zhang, Z.; Teague, H.; West, E.E.; et al. Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. Nat. Immunol. 2022, 23, 62–74.
  6. McGregor, E.; Kazemian, M.; Afzali, B.; Freiwald, T.; Yan, B.; Wang, L.; Nova-Lamperti, E.; Zhang, Z.; Teague, H.; West, E.E.; et al. An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19. bioRxiv 2020.
  7. Wimalawansa, S.J. Biology of vitamin D. J. Steroids Horm. Sci. 2019, 10, 198.
  8. Grant, W.B. Variations in Vitamin D Production Could Possibly Explain the Seasonality of Childhood Respiratory Infections in Hawaii. Pediatr. Infect. Dis. J. 2008, 27, 853.
  9. Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017, 356, i6583.
  10. Wimalawansa, S.J. Fighting against COVID-19: Boosting the immunity with micronutrients, stress reduction, physical activity, and vitamin D. Nutr. Food Sci. J. 2020, 3, 126.
  11. Chetty, V.V.; Chetty, M. Potential benefit of vitamin D supplementation in people with respiratory illnesses, during the COVID-19 pandemic. Clin. Transl. Sci. 2021, 14, 2111–2116.
  12. Wimalawansa, S.J.; Polonowita, A. Boosting immunity with vitamin D for preventing complications and deaths from COVID-19. In Proceedings of the COVID 19: Impact, Mitigation, Opportunities and Building Resilience “From Adversity to Serendipity,” Perspectives of Global Relevance Based on Research, Experience and Successes in Combating COVID-19 in Sri Lanka, Colombo, Sri Lanka, 27 January 2021; pp. 171–198.
  13. D’avolio, A.; Avataneo, V.; Manca, A.; Cusato, J.; De Nicolò, A.; Lucchini, R.; Keller, F.; Cantù, M. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients 2020, 12, 1359.
  14. DiNicolantonio, J.J.; O’keefe, J.H. Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in COVID-19 patients. Mo. Med. 2021, 118, 68–73.
  15. Cicero, A.F.G.; Fogacci, F.; Borghi, C. Vitamin D Supplementation and COVID-19 Outcomes: Mounting Evidence and Fewer Doubts. Nutrients 2022, 14, 3584.
  16. Xu, Y.; Baylink, D.J.; Chen, C.-S.; Reeves, M.E.; Xiao, J.; Lacy, C.; Lau, E.; Cao, H. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. J. Transl. Med. 2020, 18, 322.
  17. Argano, C.; Bocchio, R.M.; Natoli, G.; Scibetta, S.; Monaco, M.L.; Corrao, S. Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis. Pharmaceuticals 2023, 16, 130.
  18. Davies, G.; Mazess, R.B.; Benskin, L.L. Letter to the editor in response to the article: “Vitamin D concentrations and COVID-19 infection in UK biobank” (Hastie et al.). Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 643–644.
  19. Hastie, C.E.; Pell, J.P.; Sattar, N. Vitamin D and COVID-19 infection and mortality in UK Biobank. Eur. J. Nutr. 2020, 60, 545–548.
  20. Raisi-Estabragh, Z.; McCracken, C.; Bethell, M.S.; Cooper, J.; Cooper, C.; Caulfield, M.J.; Munroe, P.B.; Harvey, N.C.; E Petersen, S. Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: Study of 1326 cases from the UK Biobank. J. Public Health 2020, 42, 451–460.
  21. Annweiler, C.; Hanotte, B.; de L’eprevier, C.G.; Sabatier, J.-M.; Lafaie, L.; Célarier, T. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. J. Steroid Biochem. Mol. Biol. 2020, 204, 105771.
  22. Annweiler, G.; Corvaisier, M.; Gautier, J.; Dubée, V.; Legrand, E.; Sacco, G.; Annweiler, C. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study. Nutrients 2020, 12, 3377.
  23. Meltzer, D.O.; Best, T.J.; Zhang, H.; Vokes, T.; Arora, V.; Solway, J. Association of Vitamin D Deficiency and Treatment with COVID-19 Incidence. medRxiv 2020.
  24. Meltzer, D.O.; Best, T.J.; Zhang, H.; Vokes, T.; Arora, V.; Solway, J. Association of Vitamin D Status and Other Clinical Characteristics with COVID-19 Test Results. JAMA Netw. Open 2020, 3, e2019722.
  25. Radujkovic, A.; Hippchen, T.; Tiwari-Heckler, S.; Dreher, S.; Boxberger, M.; Merle, U. Vitamin D Deficiency and Outcome of COVID-19 Patients. Nutrients 2020, 12, 2757.
  26. Baktash, V.; Hosack, T.; Patel, N.; Shah, S.; Kandiah, P.; Abbeele, K.V.D.; Mandal, A.K.J.; Missouris, C.G. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad. Med. J. 2020, 97, 442–447.
  27. Greiller, C.L.; Martineau, A.R. Modulation of the Immune Response to Respiratory Viruses by Vitamin D. Nutrients 2015, 7, 4240–4270.
  28. Gönen, M.S.; Alaylıoğlu, M.; Durcan, E.; Özdemir, Y.; Şahin, S.; Konukoğlu, D.; Nohut, O.K.; Ürkmez, S.; Küçükece, B.; Balkan, I.I.; et al. Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1. Nutrients 2021, 13, 4047.
  29. Hill, A.B. The Environment and Disease: Association or Causation? Proc. R. Soc. Med. 1965, 58, 295–300.
  30. Cutolo, M.; Pizzorni, C.; Sulli, A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun. Rev. 2011, 11, 84–87.
  31. Caccamo, D.; Ricca, S.; Currò, M.; Ientile, R. Health Risks of Hypovitaminosis D: A Review of New Molecular Insights. Int. J. Mol. Sci. 2018, 19, 892.
  32. Delvin, E.; Souberbielle, J.-C.; Viard, J.-P.; Salle, B. Role of vitamin D in acquired immune and autoimmune diseases. Crit. Rev. Clin. Lab. Sci. 2014, 51, 232–247.
  33. Sîrbe, C.; Rednic, S.; Grama, A.; Pop, T.L. An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases. Int. J. Mol. Sci. 2022, 17, 9784.
  34. Gallo, D.; Baci, D.; Kustrimovic, N.; Lanzo, N.; Patera, B.; Tanda, M.L.; Piantanida, E.; Mortara, L. How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases? Int. J. Mol. Sci. 2023, 24, 4689.
  35. Székely, J.I.; Pataki, Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: A short review. Expert Rev. Respir. Med. 2012, 6, 683–704.
  36. Hassan, V.; Hassan, S.; Seyed-Javad, P.; Ahmad, K.; Asieh, H.; Maryam, S.; Farid, F.; Siavash, A. Association between Serum 25 (OH) Vitamin D Concentrations and Inflammatory Bowel Diseases (IBDs) Activity. Med. J. Malays. 2013, 68, 34–38.
  37. Sainaghi, P.P.; Bellan, M.; Nerviani, A.; Sola, D.; Molinari, R.; Cerutti, C.; Pirisi, M. Superiority of a High Loading Dose of Cholecalciferol to Correct Hypovitaminosis D in Patients with Inflammatory/Autoimmune Rheumatic Diseases. J. Rheumatol. 2013, 40, 166–172.
  38. Tuohimaa, P.; Keisala, T.; Minasyan, A.; Cachat, J.; Kalueff, A. Vitamin D, nervous system and aging. Psychoneuroendocrinology 2009, 34, S278–S286.
  39. Pani, M.; Regulla, K.; Segni, M.; Krause, M.; Hofmann, S.; Hufner, M.; Herwig, J.; Pasquino, A.; Usadel, K.; Badenhoop, K. Vitamin D 1alpha-hydroxylase (CYP1alpha) polymorphism in Graves' disease, Hashimoto's thyroiditis and type 1 diabetes mellitus. Eur. J. Endocrinol. 2002, 146, 777–781.
  40. Ganmaa, D.; Enkhmaa, D.; Nasantogtokh, E.; Sukhbaatar, S.; Tumur-Ochir, K.; Manson, J. Vitamin D, respiratory infections, and chronic disease: Review of meta-analyses and randomized clinical trials. J. Intern. Med. 2021, 291, 141–164.
  41. Vintilescu, B.; E Niculescu, C.; Stepan, M.D.; Ioniță, E. Involvement of Vitamin D in Chronic Infections of the Waldeyer`s Ring in the School Aged Child. Curr. Health Sci. J. 2019, 45, 291–295.
  42. Juszczak, A.B.; Kupczak, M.; Konecki, T. Does Vitamin Supplementation Play a Role in Chronic Kidney Disease? Nutrients 2023, 15, 2847.
  43. Özdemir, B.; Köksal, B.T.; Karakaş, N.M.; Tekindal, M.A.; Özbek, Y. Serum Vitamin D Levels in Children with Recurrent Respiratory Infections and Chronic Cough. Indian. J. Pediatr. 2016, 83, 777–782.
  44. Song, L.; Papaioannou, G.; Zhao, H.; Luderer, H.F.; Miller, C.; Dall’osso, C.; Nazarian, R.M.; Wagers, A.J.; Demay, M.B. The Vitamin D Receptor Regulates Tissue Resident Macrophage Response to Injury. Endocrinology 2016, 157, 4066–4075.
  45. Ao, T.; Kikuta, J.; Ishii, M. The Effects of Vitamin D on Immune System and Inflammatory Diseases. Biomolecules 2021, 11, 1624.
  46. Bikle, D.D. Vitamin D and the immune system: Role in protection against bacterial infection. Curr. Opin. Nephrol. Hypertens. 2008, 17, 348–352.
  47. Lin, R.; White, J.H. The pleiotropic actions of vitamin D. BioEssays 2004, 26, 21–28.
  48. Zhou, Q.; Qin, S.; Zhang, J.; Zhon, L.; Pen, Z.; Xing, T. 1,25(OH) 2 D 3 induces regulatory T cell differentiation by influencing the VDR/PLC-γ1/TGF-β1/pathway. Mol. Immunol. 2017, 91, 156–164.
  49. Baeke, F.; Takiishi, T.; Korf, H.; Gysemans, C.; Mathieu, C. Vitamin D: Modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10, 482–496.
  50. Shirvani, S.S.; Nouri, M.; Sakhinia, E.; Babaloo, Z.; Mohammadzaeh, A.; Alipour, S.; Jadideslam, G.; Khabbazi, A. The molecular and clinical evidence of vitamin D signaling as a modulator of the immune system: Role in Behçet’s disease. Immunol. Lett. 2019, 210, 10–19.
  51. Du, Y.; Tong, Y.; Quan, Y.; Wang, G.; Cheng, H.; Gu, S.; Jiang, J.X. Protein kinase A activation alleviates cataract formation via increased gap junction intercellular communication. iScience 2023, 26, 106114.
  52. Miller, S.C.; De Saint-Georges, L.; Bowman, B.M.; Jee, W.S. Bone lining cells: Structure and Function. Scanning Microsc. 1989, 3, 953–960. Available online: https://europepmc.org/article/med/2694361 (accessed on 16 January 2021).
  53. Valiunas, V. Biophysical Properties of Connexin-45 Gap Junction Hemichannels Studied in Vertebrate Cells. J. Gen. Physiol. 2002, 119, 147–164.
  54. Tikellis, C.; Thomas, M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. 2012, 2012, 256294.
  55. Wimalawansa, S.J. ACE inhibitors and angiotensin receptor blockers reduce the complications associated with COVID-19 infection. World J. Pharma Res. 2021, 10, 2579–2600.
  56. Yalcin, H.C.; Sukumaran, V.; Al-Ruweidi, M.K.A.A.; Shurbaji, S. Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms. Int. J. Mol. Sci. 2021, 22, 6703.
  57. Bradding, P.; Richardson, M.; Hinks, T.S.; Howarth, P.H.; Choy, D.F.; Arron, J.R.; Wenzel, S.E.; Siddiqui, S. ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—Implications for COVID-19. J. Allergy Clin. Immunol. 2020, 146, 208–211.
  58. Colotta, F.; Jansson, B.; Bonelli, F. Modulation of inflammatory and immune responses by vitamin D. J. Autoimmun. 2017, 85, 78–97.
  59. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.; Meinken, C.; et al. Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response. Science 2006, 311, 1770–1773.
  60. Khan, H.; Kunutsor, S.; Franco, O.H.; Chowdhury, R. Vitamin D, type 2 diabetes and other metabolic outcomes: A systematic review and meta-analysis of prospective studies. Proc. Nutr. Soc. 2013, 72, 89–97.
  61. Takiishi, T.; Gysemans, C.; Bouillon, R.; Mathieu, C. Vitamin D and Diabetes. Rheum. Dis. Clin. N. Am. 2012, 38, 179–206.
  62. Garg, M.; Rosella, O.; Rosella, G.; Wu, Y.; Lubel, J.S.; Gibson, P.R. Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease. Clin. Nutr. 2017, 37, 1375–1382.
  63. Wasse, H.; Cardarelli, F.; De Staercke, C.; Hooper, C.; Veledar, E.; Guessous, I. 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol. 2011, 12, 24.
  64. WöBke, T.K.; Sorg, B.L.; Steinhilber, D. Vitamin D in inflammatory diseases. Front. Physiol. 2014, 5, 244.
  65. Mascitelli, L.; Pezzetta, F.; Goldstein, M.R. Inflammatory bowel disease and the vitamin D endocrine system. Intern. Med. J. 2011, 41, 369–370.
  66. Raman, M.; Milestone, A.N.; Walters, J.R.; Hart, A.L.; Ghosh, S. Vitamin D and gastrointestinal diseases: Inflammatory bowel disease and colorectal cancer. Ther. Adv. Gastroenterol. 2011, 4, 49–62.
  67. Ardizzone, S.; Cassinotti, A.; Bevilacqua, M.; Clerici, M.; Porro, G.B. Vitamin D and Inflammatory Bowel Disease. Vitam. Horm. 2011, 86, 367–377.
  68. Attar, S.M. Vitamin D deficiency in rheumatoid arthritis. Prevalence and association with disease activity in Western Saudi Arabia. Saudi Med. J. 2012, 33, 520–525.
  69. Furuya, T.; Hosoi, T.; Tanaka, E.; Nakajima, A.; Taniguchi, A.; Momohara, S.; Yamanaka, H. Prevalence of and factors associated with vitamin D deficiency in 4,793 Japanese patients with rheumatoid arthritis. Clin. Rheumatol. 2013, 32, 1081–1087.
  70. Rossini, M.; Bongi, S.M.; La Montagna, G.; Minisola, G.; Malavolta, N.; Bernini, L.; Cacace, E.; Sinigaglia, L.; Di Munno, O.; Adami, S. Vitamin D deficiency in rheumatoid arthritis: Prevalence, determinants and associations with disease activity and disability. Arthritis Res. Ther. 2010, 12, R216.
  71. Ishikawa, L.L.W.; Colavite, P.M.; Fraga-Silva, T.F.d.C.; Mimura, L.A.N.; França, T.G.D.; Zorzella-Pezavento, S.F.G.; Chiuso-Minicucci, F.; Marcolino, L.D.; Penitenti, M.; Ikoma, M.R.V.; et al. Vitamin D Deficiency and Rheumatoid Arthritis. Clin. Rev. Allergy Immunol. 2017, 52, 373–388.
  72. Lin, Z.; Li, W. The Roles of Vitamin D and Its Analogs in Inflammatory Diseases. Curr. Top. Med. Chem. 2016, 16, 1242–1261.
  73. Wang, T.; Wu, M.-B.; Zhang, R.-H.; Chen, Z.-J.; Hua, C.; Lin, J.-P.; Yang, L.-R. Advances in Computational Structure-Based Drug Design and Application in Drug Discovery. Curr. Top. Med. Chem. 2016, 16, 901–916.
  74. Heine, G.; Niesner, U.; Chang, H.-D.; Steinmeyer, A.; Zügel, U.; Zuberbier, T.; Radbruch, A.; Worm, M. 1,25-dihydroxyvitamin D3promotes IL-10 production in human B cells. Eur. J. Immunol. 2008, 38, 2210–2218.
  75. Bikle, D.D. Vitamin D regulation of immune function during covid-19. Rev. Endocr. Metab. Disord. 2022, 23, 279–285.
  76. Vanherwegen, A.-S.; Gysemans, C.; Mathieu, C. Regulation of Immune Function by Vitamin D and Its Use in Diseases of Immunity. Endocrinol. Metab. Clin. N. Am. 2017, 46, 1061–1094.
  77. E Nnoaham, K.; Clarke, A. Low serum vitamin D levels and tuberculosis: A systematic review and meta-analysis. Leuk. Res. 2008, 37, 113–119.
  78. Grant, W.B.; Goldstein, M.; Mascitelli, L. Ample evidence exists from human studies that vitamin D reduces the risk of selected bacterial and viral infections. Exp. Biol. Med. 2010, 235, 1395–1396.
  79. Liu, N.; Kaplan, A.; Low, J.; Nguyen, L.; Liu, G.; Equils, O.; Hewison, M. Vitamin D Induces Innate Antibacterial Responses in Human Trophoblasts via an Intracrine Pathway1. Biol. Reprod. 2009, 80, 398–406.
  80. Vasilyevna Belyaeva, I.; Pavlovitch Churilov, L.; Robertovnsmalla, C.M.L.; Vladimirovitch Nikolaev, A.; Andreevna Starshinova, A.; Kazimirovitch Yablonsky, P. Vitamin D, Cathelicidin, Prolactin, Autoantibodies, and Cytokines in Different Forms of Pulmonary Tuberculosis versus Sarcoidosis. Isr. Med. Assoc. J. 2017, 19, 499–505.
  81. Ginde, A.A.; Mansbach, J.M.; Camargo, C.A., Jr. Association Between Serum 25-Hydroxyvitamin D Level and Upper Respiratory Tract Infection in the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2009, 169, 384–390.
  82. Berry, D.J.; Hesketh, K.; Power, C.; Hyppönen, E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. Br. J. Nutr. 2011, 106, 1433–1440.
  83. Anty, R.; Anstee, Q.M.; Gual, P.; Tran, A. Prophylaxis of bacterial infections in cirrhosis: Is an optimal 25-OH vitamin D level required? J. Hepatol. 2014, 61, 965–966.
  84. Wimalawansa, S.J. Rapidly Increasing Serum 25(OH)D Boosts the Immune System, against Infections—Sepsis and COVID-19. Nutrients 2022, 14, 2997.
  85. Grant, W.B.; Boucher, B.J.; Pludowski, P.; Wimalawansa, S.J. The emerging evidence for non-skeletal health benefits of vitamin D supplementation in adults. Nat. Rev. Endocrinol. 2022, 18, 323.
  86. Wimalawansa, S.J. Vitamin D: Everything You Need to Know; Karunaratne & Sons: Homagama, Sri Lanka, 2012; Volume 1.0, ISBN 978-955-9098-94-2.
  87. Wimalawansa, S.J. Non-musculoskeletal benefits of vitamin D. J. Steroid Biochem. Mol. Biol. 2018, 175, 60–81.
  88. Armas, L.A.G.; Hollis, B.W.; Heaney, R.P. Vitamin D2 Is Much Less Effective than Vitamin D3 in Humans. J. Clin. Endocrinol. Metab. 2004, 89, 5387–5391.
  89. Urashima, M.; Mezawa, H.; Noya, M.; Camargo, C.A., Jr. Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic: A randomized controlled trial. Food Funct. 2014, 5, 2365–2370.
  90. White, J.H. Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch. Biochem. Biophys. 2012, 523, 58–63.
  91. Wimalawansa, S. Overcoming Infections Including COVID-19, by Maintaining Circulating 25(OH)D Concentrations Above 50 ng/mL. Pathol. Lab. Med. Int. 2022, ume 14, 37–60.
  92. Wimalawansa, S.J.; Whittle, R. Vitamin D: A single initial dose is not bogus if followed by an appropriate maintenance intake. JBMR Plus 2022, 6, e10606.
  93. Trochoutsou, A.I.; Kloukina, V.; Samitas, K.; Xanthou, G. Vitamin-D in the Immune System: Genomic and Non-Genomic Actions. Mini-Rev. Med. Chem. 2015, 15, 953–963.
  94. Bravo, S.; Paredes, R.; Izaurieta, P.; Lian, J.B.; Stein, J.L.; Stein, G.S.; Hinrichs, M.V.; Olate, J.; Aguayo, L.G.; Montecino, M. The classic receptor for 1α,25-dihydroxy vitamin D3 is required for non-genomic actions of 1α,25-dihydroxy vitamin D3 in osteosarcoma cells. J. Cell. Biochem. 2006, 99, 995–1000.
  95. Hii, C.S.; Ferrante, A. The Non-Genomic Actions of Vitamin D. Nutrients 2016, 8, 135.
  96. Stio, M.; Retico, L.; Annese, V.; Bonanomi, A.G. Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scand. J. Gastroenterol. 2016, 51, 1193–1199.
  97. Valdés-López, J.F.; Velilla, P.; Urcuqui-Inchima, S. Vitamin D modulates the expression of Toll-like receptors and pro-inflammatory cytokines without affecting Chikungunya virus replication, in monocytes and macrophages. Acta Trop. 2022, 232, 106497.
  98. Ellfolk, M.; Norlin, M.; Wikvall, K. Isolation and properties of the CYP2D25 promoter: Transcriptional regulation by vitamin D3 metabolites. Biochem. Biophys. Res. Commun. 2006, 345, 568–572.
  99. Oristrell, J.; Oliva, J.C.; Subirana, I.; Casado, E.; Domínguez, D.; Toloba, A.; Aguilera, P.; Esplugues, J.; Fafián, P.; Grau, M. Association of Calcitriol Supplementation with Reduced COVID-19 Mortality in Patients with Chronic Kidney Disease: A Population-Based Study. Biomedicines 2021, 9, 509.
  100. Xu, J.; Sriramula, S.; Xia, H.; Moreno-Walton, L.; Culicchia, F.; Domenig, O.; Poglitsch, M.; Lazartigues, E. Clinical Relevance and Role of Neuronal AT 1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. Circ. Res. 2017, 121, 43–55.
  101. Xu, J.; Yang, J.; Chen, J.; Luo, Q.; Zhang, Q.; Zhang, H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol. Med. Rep. 2017, 16, 7432–7438.
  102. Kato, S.; Nishimura, K.-I.; Mori, J.-I. Update on recent progress in vitamin D research. Molecular basis of epigenetic regulation by vitamin D via its nuclear receptor. Clin. Calcium 2017, 27, 1543–1550.
  103. Hossein-Nezhad, A.; Holick, M.F. Vitamin D for Health: A Global Perspective. Mayo Clin. Proc. 2013, 88, 720–755.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Primary Health Care
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Sunil J. Wimalawansa
View Times: 908
Revisions: 2 times (View History)
Update Date: 06 Sep 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback